|8. Switch to an IL-17i biologic over tofacitinib (PICO 75)|Low (90–93, 105)|
|Conditional recommendation based on low-quality evidence; may consider tofacitinib if the patient prefers an oral therapy or in patients with concomitant IBD or a history of recurrent Candida infections.| |
|9. Switch to an IL-12/23i biologic over abatacept (PICO 71)|Low (99, 100, 103, 104)|
|Conditional recommendation based on low-quality evidence; may consider abatacept if the patient prefers IV dosing or in patients with recurrent or serious infections.| |
|10. Switch to an IL-12/23i biologic over tofacitinib (PICO 74)|Low (98–100, 105)|
|Conditional recommendation based on low-quality evidence; may consider tofacitinib if the patient prefers an oral therapy.| |
|11. Switch to a different TNFi biologic monotherapy over switching to a different TNFi biologic and MTX combination therapy (PICO 30)|Very low|